Taki ChemicalTaki Chemical Co., Ltd.4025東証プライム化学FY ending Dec 2025, consolidated, J-GAAP
Out of every ¥100 of sales, about ¥7 is left as operating profit. Revenue changed +7.9% from the prior year, operating profit +18.6%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2021 | 5.8% | 0.71× | 4.2% | 1.73× | 7.2% |
| 2022 | 5.7% | 0.74× | 4.3% | 1.75× | 7.5% |
| 2023 | 3.9% | 0.69× | 2.7% | 1.78× | 4.8% |
| 2024 | 5.9% | 0.71× | 4.2% | 1.85× | 7.8% |
| 2025 | 7.8% | 0.68× | 5.3% | 1.96× | 10.3% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 32,812 | 35,846 | 34,852 | 38,916 | 41,977 |
| Cost of revenue | 24,247 | 27,040 | 27,922 | 29,908 | 31,735 |
| Gross profit | 8,564 | 8,805 | 6,929 | 9,008 | 10,242 |
| SG&A | 5,906 | 6,053 | 6,016 | 6,339 | 7,078 |
| Operating income | 2,658 | 2,751 | 912 | 2,668 | 3,163 |
| Pretax income | 2,679 | 3,038 | 1,956 | 3,262 | 4,374 |
| Income tax | 763 | 1,015 | 628 | 964 | 1,081 |
| Net income attributable to owners | 1,916 | 2,056 | 1,356 | 2,299 | 3,277 |
| Operating margin | 8.1% | 7.7% | 2.6% | 6.9% | 7.5% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥6.43B | ¥6.26B | ¥5.08B | ¥7.46B | ¥7.26B |
| Total assets | ¥46B | ¥50.3B | ¥51.3B | ¥58.4B | ¥65.7B |
| Net assets | ¥29.4B | ¥32.1B | ¥33.9B | ¥38B | ¥43.3B |
| Share capital | ¥2.15B | ¥2.15B | ¥2.15B | ¥2.15B | ¥2.15B |
| Trade receivables | ¥8.96B | ¥10B | ¥9.23B | ¥10.3B | ¥11B |
| Property, plant and equipment | ¥15.8B | ¥15.3B | ¥16.4B | ¥17B | ¥17.8B |
| Intangible assets excluding goodwill | ¥522M | ¥418M | ¥326M | ¥293M | ¥418M |
| Goodwill | — | — | — | — | ¥82M |
| Investment securities | ¥7.07B | ¥8.36B | ¥10.6B | ¥13.6B | ¥17.2B |
| Current assets | ¥22.4B | ¥26B | ¥23.8B | ¥27.3B | ¥29.8B |
| Current liabilities | ¥8.6B | ¥9.97B | ¥8.5B | ¥10.5B | ¥11.2B |
| Trade payables | ¥4.98B | ¥6.79B | ¥5.9B | ¥6.7B | ¥7.48B |
| Short-term borrowings | ¥376M | ¥369M | ¥373M | ¥529M | ¥454M |
| Long-term borrowings | ¥455M | ¥395M | ¥335M | ¥283M | ¥398M |
| Total liabilities | ¥16.7B | ¥18.3B | ¥17.4B | ¥20.4B | ¥22.3B |
| Non-controlling interests | ¥142M | ¥108M | ¥79M | ¥77M | ¥440M |
| Equity attributable to owners of parent | ¥26.7B | ¥28.3B | ¥28.6B | ¥30.6B | ¥32.8B |
| Retained earnings | ¥23.9B | ¥25.5B | ¥26.4B | ¥28.3B | ¥31.1B |
| Treasury stock | -¥736M | -¥729M | -¥1.37B | -¥1.35B | -¥1.96B |
EDINET (FSA Japan)
有価証券報告書－第107期(2025/01/01－2025/12/31)
EDINET (FSA Japan)
有価証券報告書－第106期(2024/01/01－2024/12/31)
EDINET (FSA Japan)
有価証券報告書－第105期(2023/01/01－2023/12/31)
EDINET (FSA Japan)
有価証券報告書－第104期(2022/01/01－2022/12/31)
EDINET (FSA Japan)
訂正有価証券報告書－第103期(令和3年1月1日－令和3年12月31日)
EDINET (FSA Japan)
有価証券報告書－第102期(令和2年1月1日－令和2年12月31日)
Extracted from XBRL: 55 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.